Tripp Levy PLLC investigating the acquisition of Zalicus Inc.

April 16, 2014
New York, New York

Tripp Levy PLLC, a leading national securities and shareholder rights law firm announces that it is investigating the acquisition of Zalicus Inc. on behalf of its shareholders. Zalicus Inc. and Epirus Biopharmaceuticals, Inc., announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction. Following closing, Zalicus will be re-named Epirus Biopharmaceuticals, Inc., and will operate under the leadership of the Epirus management team. Zalicus shareholders will only own approx. 14% of the new company.

The investigation concerns whether the board of directors of Zalicus breached their fiduciary duties by not engaging in a full and fair auction to insure that shareholders obtained the maximum value for their shares. If you are a shareholder of Zalicus and would like additional information regarding this matter at no cost or expense including how you can join with other shareholders who are seeking a higher price please contact us toll free at 1-877-772-3975 or contact us via our website.

Tripp Levy PLLC is a leading national law firm that along with its affiliates have recovered billions of dollars for shareholders around the globe. Attorney advertising. Prior results do not indicate as similar outcome